Singapore's Biobot Surgical Raises $15M to Bring Robotic Prostate Cancer Platform to US Patients

Biobot Surgical a Singapore medical tech firm has raised 20 million Singapore dollars to grow its robotic tools for prostate cancer care.

The money will help the company push its Mona Lisa system into the United States market while building more proof of its benefits.

Why Robotic Tools Change Prostate Care

Traditional prostate biopsies often miss cancer spots because they rely on random needle placement without clear imaging guidance.

The new platform uses robots to guide needles with MRI and ultrasound fusion so doctors can hit exact targets and treat only the diseased tissue.

This approach reduces side effects like incontinence that come with full gland removal and gives men faster recovery times.

Prostate cancer hits more than 1.4 million men each year worldwide so better precision tools matter for millions of families.

What the Funding Means for Patients and the Future

With over 80 systems already used on 30,000 patients in Europe and Asia the company has real world proof that the technology works safely.

US entry plans include work with experts to match the tools with doctors who need them most and to gather fresh data on costs and outcomes.

Over time this could lower overall healthcare spending by cutting repeat procedures and hospital stays while opening access in more clinics.

Looking ahead the platform may expand beyond biopsies to full focal treatments creating a complete robotic solution for prostate health.

For everyday men this means more accurate diagnosis earlier treatment and a real chance to avoid the harshest effects of cancer surgery.